TLOG (TetraLogic Pharmaceuticals) Debt-to-Asset : 0.72 (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TetraLogic Pharmaceuticals Debt-to-Asset?

TetraLogic Pharmaceuticals TLOG -97.50% Debt-to-Asset is 0.72 as of Sep. 2016.

TetraLogic Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $30.81 Mil. TetraLogic Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2016 was $42.79 Mil. TetraLogic Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2016 was 0.72.

TetraLogic Pharmaceuticals  (OTCPK:TLOG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

TetraLogic Pharmaceuticals Debt-to-Asset Related Terms

TetraLogic Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals Debt-to-Asset Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-Asset
0.00 0.97 0.00 0.23 0.44

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.44 0.51 0.59 0.72

TLOG vs ARGSQ, GTHR, SOAN: Debt-to-Asset Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Debt-to-Asset falls into.


TetraLogic Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

TetraLogic Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 28.279) / 64.021
=0.44

TetraLogic Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2016 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 30.809) / 42.788
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.72 mean?
TetraLogic Pharmaceuticals (TLOG) has a Debt-to-Asset of 0.72 as of Sep. 2016. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' Debt-to-Asset too high?
TetraLogic Pharmaceuticals' current Debt-to-Asset is 0.72.
How does TetraLogic Pharmaceuticals' Debt-to-Asset compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' Debt-to-Asset of 0.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on TetraLogic Pharmaceuticals and its competitors. TetraLogic Pharmaceuticals's current Debt-to-Asset is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current Debt-to-Asset of 0.72. The current Debt-to-Asset is 0.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current Debt-to-Asset is 0.72 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.